Literature DB >> 7784057

Cyclin D2 is a moderately oscillating nucleoprotein required for G1 phase progression in specific cell types.

J Lukas1, J Bartkova, M Welcker, O W Petersen, G Peters, M Strauss, J Bartek.   

Abstract

To explore regulation and function of cyclin D2, a candidate cell cycle-regulatory proto-oncogene, we examined subcellular localisation, cell type- and cell cycle-dependent expression, and requirement of cyclin D2 protein for G1 progression, in a panel of 40 human normal and cancer cell types. Except for lymphoid cells and sarcoma cell lines, expression of cyclin D2 was considerably more restricted than that of cyclin D1, whereas both D-type cyclin proteins were low or undetectable in cells lacking functional retinoblastoma gene product. In G1 cells, the cyclin D2 protein was more resistant to extraction and localised predominantly to nuclei, whereas it became more soluble and distributed in both nuclei and cytoplasm from G1/S transition onwards. Centrifugal elutriation and multiparameter flow cytometry analyses of several cell types showed moderate cell cycle oscillation with maximum levels of the cyclin D2 protein reached in late G1. Microinjection and/or electroporation of antibodies to cyclin D2 during G1 arrested the cyclin D2-expressing lymphocytes, breast myoepithelium, and U-2-OS sarcoma cells in G1 phase, whereas cyclin D2-negative cell types were unaffected by such treatment. Consistent with the putative proto-oncogenic role of cyclin D2 in specific cell types, our data show that this G1 cyclin has properties closely resembling those of cyclin D1, including the essential positive role in regulation of G1.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7784057

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  31 in total

Review 1.  Integration of the pRB and p53 cell cycle control pathways.

Authors:  C L Stewart; A M Soria; P A Hamel
Journal:  J Neurooncol       Date:  2001-02       Impact factor: 4.130

Review 2.  Cell cycle genes in a mouse mammary hyperplasia model.

Authors:  Thenaa K Said; Daniel Medina
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

3.  Increased expression of cyclin D2 during multiple states of growth arrest in primary and established cells.

Authors:  M Meyyappan; H Wong; C Hull; K T Riabowol
Journal:  Mol Cell Biol       Date:  1998-06       Impact factor: 4.272

4.  Sustained activation of extracellular-signal-regulated kinase 1 (ERK1) is required for the continued expression of cyclin D1 in G1 phase.

Authors:  J D Weber; D M Raben; P J Phillips; J J Baldassare
Journal:  Biochem J       Date:  1997-08-15       Impact factor: 3.857

5.  Transfer of macromolecules into living adult cardiomyocytes by microinjection.

Authors:  M Bartoli; W C Claycomb
Journal:  Mol Cell Biochem       Date:  1997-07       Impact factor: 3.396

Review 6.  Cyclins and breast cancer.

Authors:  Robert L Sutherland; Elizabeth A Musgrove
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

7.  Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance.

Authors:  Pankaj Taneja; Dejan Maglic; Fumitake Kai; Sinan Zhu; Robert D Kendig; Elizabeth A Fry; Kazushi Inoue
Journal:  Clin Med Insights Oncol       Date:  2010-04-20

8.  Identity of adenylyl cyclase isoform determines the rate of cell cycle progression in NIH 3T3 cells.

Authors:  M J Smit; D Verzijl; R Iyengar
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

9.  Cyclin D2 translocates p27 out of the nucleus and promotes its degradation at the G0-G1 transition.

Authors:  Etsuo Susaki; Keiko Nakayama; Keiichi I Nakayama
Journal:  Mol Cell Biol       Date:  2007-04-23       Impact factor: 4.272

10.  Widespread shortening of 3'UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells.

Authors:  Christine Mayr; David P Bartel
Journal:  Cell       Date:  2009-08-21       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.